{ "data": { "id": "org_iqvia-institute", "slug": "iqvia-institute", "name": "IQVIA Institute", "short_name": "IQVIA", "type": "research", "tier": 3, "homepage": "https://www.iqvia.com", "country_code": "US", "reliability_note": null, "url": "https://statorigin.org/sources/iqvia-institute", "documents": [ { "title": "Global Medicine Use Trends 2026", "url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-medicine-use-trends-2026", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok", "statistic_count": 30 }, { "title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok", "statistic_count": 22 }, { "title": "Global R&D Trends 2026", "url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok", "statistic_count": 35 }, { "title": "Rethinking Clinical Trial Country Prioritization", "url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok", "statistic_count": 33 }, { "title": "IQVIA Institute’s Global R&D Trends 2026 Report Finds Credible Signal on AI-Enabled Programs", "url": "https://www.iqvia.com/blogs/2026/05/iqvia-institutes-global-r-and-d-trends-2026-report-finds-credible-signal-on-ai-enabled-programs", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok", "statistic_count": 1 }, { "title": "Supporting patients through research collaboration", "url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-16", "license": "see-source", "url_status": "ok", "statistic_count": 10 }, { "title": "Global Oncology Trends 2025", "url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-16", "license": "see-source", "url_status": "ok", "statistic_count": 57 }, { "title": "Global R&D Trends 2026", "url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok", "statistic_count": 35 }, { "title": "U.S. Medicine Use Trends 2026", "url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok", "statistic_count": 56 } ], "statistics": [ { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGD5", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD5", "indicator": { "slug": "additional-novel-active-substance-launches", "name": "Additional novel active substance launches", "definition": "Projected cumulative expansion in the number of novel active substances launched over the next five years." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2030-12-31", "type": "year" }, "value": 375, "value_text": "350–400", "unit": "count", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026", "document_type": "press_release", "locator": "Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025", "quote": "Based on molecules in the late-stage pipeline and historic success rates, over the next five years an average of 70–80 NAS are expected to launch annually, expanding the number of NAS launched globally by 350–400.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2030). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD5", "bibtex": "@misc{iqvia2030additionalbjmgd5,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD5},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_QK71C25ECSWX5EXPXESRZ555R9", "url": "https://statorigin.org/stat/stat_QK71C25ECSWX5EXPXESRZ555R9", "indicator": { "slug": "aggregate-revenue-of-patient-organizations", "name": "Aggregate revenue of patient organizations", "definition": "Total combined revenue of patient organizations over a multi-year period." }, "industry": [ { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2016-01-01", "end": "2020-12-31", "type": "year" }, "value": 62.5, "value_text": "$62.5 billion", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Supporting patients through research collaboration", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration", "document_type": "press_release", "locator": "Over the past 5 years patient organizations have received over 62.5 billion in revenue", "quote": "Aggregate revenue of U.S. patient organizations exceeded $62.5 billion over the five-year period 2016–2020 (n=3,262), giving them an average of $12.5 billion annually to support their missions.", "published_date": null, "accessed_at": "2026-09-16", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T01:20:11.850Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2020). Supporting patients through research collaboration. Retrieved September 16, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration. Via StatOrigin, https://statorigin.org/stat/stat_QK71C25ECSWX5EXPXESRZ555R9", "bibtex": "@misc{iqvia2020aggregatez555r9,\n author = {{IQVIA Institute}},\n title = {Supporting patients through research collaboration},\n year = {2020},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_QK71C25ECSWX5EXPXESRZ555R9},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration. Accessed September 16, 2026.}\n}" }, "updated_at": "2026-09-17T01:20:11.850Z" }, { "id": "stat_HTN3S09ZN6YTRFG5A3YBJWTHTF", "url": "https://statorigin.org/stat/stat_HTN3S09ZN6YTRFG5A3YBJWTHTF", "indicator": { "slug": "annual-revenue-growth-rate-of-largest-patient-organizations", "name": "Annual revenue growth rate of largest patient organizations", "definition": "Average annual revenue growth rate for the largest patient organizations by revenue tier." }, "industry": [ { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2016-01-01", "end": "2020-12-31", "type": "year" }, "value": 5, "value_text": "5% annually", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Supporting patients through research collaboration", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration", "document_type": "press_release", "locator": "Over the past 5 years patient organizations have received over 62.5 billion in revenue", "quote": "However, the top 20% of patient organizations among these (n=377) raised 92% of this revenue and only these largest patient organizations have seen their revenues grow on average (with increases of 5% annually) while others have seen declines.", "published_date": null, "accessed_at": "2026-09-16", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T01:20:11.850Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2020). Supporting patients through research collaboration. Retrieved September 16, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration. Via StatOrigin, https://statorigin.org/stat/stat_HTN3S09ZN6YTRFG5A3YBJWTHTF", "bibtex": "@misc{iqvia2020revenuejwthtf,\n author = {{IQVIA Institute}},\n title = {Supporting patients through research collaboration},\n year = {2020},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_HTN3S09ZN6YTRFG5A3YBJWTHTF},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration. Accessed September 16, 2026.}\n}" }, "updated_at": "2026-09-17T01:20:11.850Z" }, { "id": "stat_H93DP1YSR3ZJAABE7G8HHBBMY2", "url": "https://statorigin.org/stat/stat_H93DP1YSR3ZJAABE7G8HHBBMY2", "indicator": { "slug": "average-annual-growth-in-cancer-medicine-spending", "name": "Average annual growth in cancer medicine spending", "definition": "Compound or average annual percentage growth rate of expenditure on cancer medicines over a specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2020-01-01", "end": "2024-12-31", "type": "year" }, "value": 11.9, "value_text": "11.9%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global Oncology Trends 2025", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025", "document_type": "press_release", "locator": "Other Findings", "quote": "Growth in spending averaged 11.9% annually 2020–2024, with a brief slow down in 2022 as countries continued to recover from the COVID-19 pandemic and volume growth was flat.", "published_date": null, "accessed_at": "2026-09-16", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2024). Global Oncology Trends 2025. Retrieved September 16, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Via StatOrigin, https://statorigin.org/stat/stat_H93DP1YSR3ZJAABE7G8HHBBMY2", "bibtex": "@misc{iqvia2024averagehbbmy2,\n author = {{IQVIA Institute}},\n title = {Global Oncology Trends 2025},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_H93DP1YSR3ZJAABE7G8HHBBMY2},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Accessed September 16, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGD4", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD4", "indicator": { "slug": "average-annual-novel-active-substance-launches", "name": "Average annual novel active substance launches", "definition": "Average number of novel active substances expected to launch per year over the next five years." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2030-12-31", "type": "year" }, "value": 75, "value_text": "70–80", "unit": "count", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026", "document_type": "press_release", "locator": "Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025", "quote": "Based on molecules in the late-stage pipeline and historic success rates, over the next five years an average of 70–80 NAS are expected to launch annually, expanding the number of NAS launched globally by 350–400.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2030). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD4", "bibtex": "@misc{iqvia2030averagebjmgd4,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD4},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_6AVR24ZCJXYSH9BAK44EDR538J", "url": "https://statorigin.org/stat/stat_6AVR24ZCJXYSH9BAK44EDR538J", "indicator": { "slug": "average-annual-oncology-novel-active-substance-launches-multi-year-total", "name": "Average annual oncology novel active substance launches (multi-year total)", "definition": "Average annual count of oncology novel active substances launched across a multi-year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2020-01-01", "end": "2024-12-31", "type": "year" }, "value": 26, "value_text": "26", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global Oncology Trends 2025", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025", "document_type": "press_release", "locator": "Key Findings: Oncology continues to see significant novel medicine launches", "quote": "Twenty-five oncology novel active substances (NAS) were launched globally in 2024, and the average number of new launches annually from 2020–2024 was 26 compared to an average of 16 in the five years prior", "published_date": null, "accessed_at": "2026-09-16", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2024). Global Oncology Trends 2025. Retrieved September 16, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Via StatOrigin, https://statorigin.org/stat/stat_6AVR24ZCJXYSH9BAK44EDR538J", "bibtex": "@misc{iqvia2024averagedr538j,\n author = {{IQVIA Institute}},\n title = {Global Oncology Trends 2025},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_6AVR24ZCJXYSH9BAK44EDR538J},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Accessed September 16, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_79Y2030QGZNMCGK0AX147EFQTS", "url": "https://statorigin.org/stat/stat_79Y2030QGZNMCGK0AX147EFQTS", "indicator": { "slug": "average-annual-oncology-novel-active-substance-launches-multi-year-total", "name": "Average annual oncology novel active substance launches (multi-year total)", "definition": "Average annual count of oncology novel active substances launched across a multi-year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2015-01-01", "end": "2019-12-31", "type": "year" }, "value": 16, "value_text": "16", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global Oncology Trends 2025", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025", "document_type": "press_release", "locator": "Key Findings: Oncology continues to see significant novel medicine launches", "quote": "Twenty-five oncology novel active substances (NAS) were launched globally in 2024, and the average number of new launches annually from 2020–2024 was 26 compared to an average of 16 in the five years prior", "published_date": null, "accessed_at": "2026-09-16", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2019). Global Oncology Trends 2025. Retrieved September 16, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Via StatOrigin, https://statorigin.org/stat/stat_79Y2030QGZNMCGK0AX147EFQTS", "bibtex": "@misc{iqvia2019average7efqts,\n author = {{IQVIA Institute}},\n title = {Global Oncology Trends 2025},\n year = {2019},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_79Y2030QGZNMCGK0AX147EFQTS},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Accessed September 16, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_4KYVSDW7F7ZQR4H63CZFXATPSK", "url": "https://statorigin.org/stat/stat_4KYVSDW7F7ZQR4H63CZFXATPSK", "indicator": { "slug": "average-annual-revenue-of-patient-organizations", "name": "Average annual revenue of patient organizations", "definition": "Average yearly revenue of patient organizations over a multi-year period." }, "industry": [ { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2016-01-01", "end": "2020-12-31", "type": "year" }, "value": 12.5, "value_text": "$12.5 billion", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "estimate", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Supporting patients through research collaboration", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration", "document_type": "press_release", "locator": "Over the past 5 years patient organizations have received over 62.5 billion in revenue", "quote": "Aggregate revenue of U.S. patient organizations exceeded $62.5 billion over the five-year period 2016–2020 (n=3,262), giving them an average of $12.5 billion annually to support their missions.", "published_date": null, "accessed_at": "2026-09-16", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T01:20:11.850Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2020). Supporting patients through research collaboration. Retrieved September 16, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration. Via StatOrigin, https://statorigin.org/stat/stat_4KYVSDW7F7ZQR4H63CZFXATPSK", "bibtex": "@misc{iqvia2020averagexatpsk,\n author = {{IQVIA Institute}},\n title = {Supporting patients through research collaboration},\n year = {2020},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_4KYVSDW7F7ZQR4H63CZFXATPSK},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration. Accessed September 16, 2026.}\n}" }, "updated_at": "2026-09-17T01:20:11.850Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNA", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNA", "indicator": { "slug": "covid-19-vaccines-and-therapeutics-spending-decline", "name": "COVID-19 vaccines and therapeutics spending decline", "definition": "Annual decline in spending on COVID-19 vaccines and antiviral therapeutics." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 4, "value_text": "$4 billion", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "COVID‑19 vaccines and therapeutics, which contributed to spending growth in 2024, declined by $4 billion in 2025.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNA", "bibtex": "@misc{iqvia2025covidkt7nna,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNA},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_BJ7HZRV3A29CRCTK4XSQH36G3Y", "url": "https://statorigin.org/stat/stat_BJ7HZRV3A29CRCTK4XSQH36G3Y", "indicator": { "slug": "cancer-medicine-spending", "name": "Cancer medicine spending", "definition": "Total expenditure on oncology medicines measured at invoice or list prices." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 252, "value_text": "$252Bn", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global Oncology Trends 2025", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025", "document_type": "press_release", "locator": "Key Findings: Spending on oncology medicines is growing across geographies and tumors", "quote": "Cancer medicine spending at list prices rose to $252Bn globally in 2024 and is expected to reach $441Bn by 2029", "published_date": null, "accessed_at": "2026-09-16", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2024). Global Oncology Trends 2025. Retrieved September 16, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Via StatOrigin, https://statorigin.org/stat/stat_BJ7HZRV3A29CRCTK4XSQH36G3Y", "bibtex": "@misc{iqvia2024cancerh36g3y,\n author = {{IQVIA Institute}},\n title = {Global Oncology Trends 2025},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_BJ7HZRV3A29CRCTK4XSQH36G3Y},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Accessed September 16, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_J7D90EZ7P8DZ9NMB54NT6SN5MM", "url": "https://statorigin.org/stat/stat_J7D90EZ7P8DZ9NMB54NT6SN5MM", "indicator": { "slug": "cancer-medicine-spending", "name": "Cancer medicine spending", "definition": "Total expenditure on oncology medicines measured at invoice or list prices." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2029-01-01", "end": "2029-12-31", "type": "year" }, "value": 441, "value_text": "$441Bn", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global Oncology Trends 2025", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025", "document_type": "press_release", "locator": "Key Findings: Spending on oncology medicines is growing across geographies and tumors", "quote": "Cancer medicine spending at list prices rose to $252Bn globally in 2024 and is expected to reach $441Bn by 2029", "published_date": null, "accessed_at": "2026-09-16", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2029). Global Oncology Trends 2025. Retrieved September 16, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Via StatOrigin, https://statorigin.org/stat/stat_J7D90EZ7P8DZ9NMB54NT6SN5MM", "bibtex": "@misc{iqvia2029cancer6sn5mm,\n author = {{IQVIA Institute}},\n title = {Global Oncology Trends 2025},\n year = {2029},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_J7D90EZ7P8DZ9NMB54NT6SN5MM},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Accessed September 16, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNR", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNR", "indicator": { "slug": "cell-and-gene-therapy-clinical-trial-starts", "name": "Cell and gene therapy clinical trial starts", "definition": "Number of clinical trials of cell and gene therapies started in a given period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true }, { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": false } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2019-01-01", "end": "2023-12-31", "type": "year" }, "value": 3285, "value_text": "3,285", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Cell and gene therapy clinical trial starts by type, 2013-2023", "quote": "Over the last five years 3,285 trials were started to evaluate cell and gene therapies in patients across all sponsor types, including 631 in 2023.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNR", "bibtex": "@misc{iqvia2023cellkt7nnr,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNR},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNS", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNS", "indicator": { "slug": "cell-and-gene-therapy-clinical-trial-starts", "name": "Cell and gene therapy clinical trial starts", "definition": "Number of clinical trials of cell and gene therapies started in a given period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true }, { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": false } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 631, "value_text": "631", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Cell and gene therapy clinical trial starts by type, 2013-2023", "quote": "Over the last five years 3,285 trials were started to evaluate cell and gene therapies in patients across all sponsor types, including 631 in 2023.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNS", "bibtex": "@misc{iqvia2023cellkt7nns,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNS},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_M11EYSSCNPVP9SXHQP9D3E44F2", "url": "https://statorigin.org/stat/stat_M11EYSSCNPVP9SXHQP9D3E44F2", "indicator": { "slug": "cell-and-gene-therapy-cumulative-launches", "name": "Cell and gene therapy cumulative launches", "definition": "Cumulative number of distinct cell and gene therapies that have received regulatory approval and launched commercially." }, "industry": [ { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-12-31", "end": "2023-12-31", "type": "point" }, "value": 76, "value_text": "76", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Key findings", "quote": "As of the end of 2023, 76 cell and gene therapies have been launched globally, more than double the number of therapies that had been launched by 2013.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T01:20:11.850Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_M11EYSSCNPVP9SXHQP9D3E44F2", "bibtex": "@misc{iqvia2023cell3e44f2,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_M11EYSSCNPVP9SXHQP9D3E44F2},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T01:20:11.850Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNZ", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNZ", "indicator": { "slug": "cell-and-gene-therapy-reimbursement-rate", "name": "Cell and gene therapy reimbursement rate", "definition": "Percentage of cell and gene therapies that are reimbursed in a given country or region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true }, { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": false } ], "region": { "code": "EU", "name": "European Union", "type": "bloc" }, "period": { "start": "2023-04-01", "end": "2023-04-01", "type": "point" }, "value": 42, "value_text": "42%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Status of cell and gene therapy reimbursement in Europe (Apr 2023) compared to GDP per capital 2022, current international dollars PPP", "quote": "Within Western Europe, the wealthiest countries — Luxembourg and Switzerland — reimburse fewer therapies (42%) than Germany and France, which have lower GDP per capita but reimburse 75% or more of therapies.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNZ", "bibtex": "@misc{iqvia2023cellkt7nnz,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNZ},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_7J64CQDPE38R0DC4ACBET5KH2X", "url": "https://statorigin.org/stat/stat_7J64CQDPE38R0DC4ACBET5KH2X", "indicator": { "slug": "cell-and-gene-therapy-reimbursement-rate", "name": "Cell and gene therapy reimbursement rate", "definition": "Percentage of cell and gene therapies that are reimbursed in a given country or region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "EU", "name": "European Union", "type": "bloc" }, "period": { "start": "2023-04-01", "end": "2023-04-30", "type": "month" }, "value": 42, "value_text": "42%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Status of cell and gene therapy reimbursement in Europe (Apr 2023) compared to GDP per capital 2022, current international dollars PPP", "quote": "Within Western Europe, the wealthiest countries — Luxembourg and Switzerland — reimburse fewer therapies (42%) than Germany and France, which have lower GDP per capita but reimburse 75% or more of therapies.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_7J64CQDPE38R0DC4ACBET5KH2X", "bibtex": "@misc{iqvia2023cellt5kh2x,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_7J64CQDPE38R0DC4ACBET5KH2X},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNE", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNE", "indicator": { "slug": "cell-and-gene-therapy-share-of-medicine-spending", "name": "Cell and gene therapy share of medicine spending", "definition": "Percentage of total medicine spending attributable to cell and gene therapies." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true }, { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": false } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 0.4, "value_text": "0.4%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Key findings", "quote": "Spending on cell and gene therapies is increasing rapidly and reached $5.9Bn in 2023, up 38% from 2022 although spending accounted for only 0.4% of the $1.6Tn spent on medicines globally in 2023.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNE", "bibtex": "@misc{iqvia2023cellkt7nne,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNE},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNT", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNT", "indicator": { "slug": "cell-and-gene-therapy-spending", "name": "Cell and gene therapy spending", "definition": "Total spending on cell and gene therapies in a given year." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true }, { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": false } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 5.9, "value_text": "$5.9Bn", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Global cell and gene therapy spending and share by geography", "quote": "Global spending on these therapies reached $5.9Bn in 2023.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNT", "bibtex": "@misc{iqvia2023cellkt7nnt,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNT},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNW", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNW", "indicator": { "slug": "cell-and-gene-therapy-spending-average-annual-growth-rate", "name": "Cell and gene therapy spending average annual growth rate", "definition": "Average annual percentage growth in cell and gene therapy spending over a multi-year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true }, { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": false } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2019-01-01", "end": "2023-12-31", "type": "year" }, "value": 65, "value_text": "65%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Global cell and gene therapy spending and share by geography", "quote": "Spending grew by 38% in 2023 from the prior year, and spending has averaged 65% annual growth over the last five years as more products are reaching the market.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNW", "bibtex": "@misc{iqvia2023cellkt7nnw,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNW},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_KZMQKVXHWFTKJV7T310W619CKK", "url": "https://statorigin.org/stat/stat_KZMQKVXHWFTKJV7T310W619CKK", "indicator": { "slug": "cell-and-gene-therapy-spending-growth-rate", "name": "Cell and gene therapy spending growth rate", "definition": "Year-over-year percentage growth in spending on cell and gene therapies." }, "industry": [ { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": true }, { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": false } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 38, "value_text": "38%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Key findings", "quote": "Spending on cell and gene therapies is increasing rapidly and reached $5.9Bn in 2023, up 38% from 2022 although spending accounted for only 0.4% of the $1.6Tn spent on medicines globally in 2023.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T01:20:11.850Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_KZMQKVXHWFTKJV7T310W619CKK", "bibtex": "@misc{iqvia2023cell619ckk,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_KZMQKVXHWFTKJV7T310W619CKK},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T01:20:11.850Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNX", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNX", "indicator": { "slug": "cell-and-gene-therapy-spending-share-by-geography", "name": "Cell and gene therapy spending share by geography", "definition": "Percentage of cell and gene therapy spending attributable to a given geography." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 62, "value_text": "62%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Global cell and gene therapy spending and share by geography", "quote": "A majority (62%) of this spending is attributable to U.S. sales, compared to just 38% coming from other geographies.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNX", "bibtex": "@misc{iqvia2023cellkt7nnx,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNX},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNY", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNY", "indicator": { "slug": "cell-and-gene-therapy-spending-share-by-geography", "name": "Cell and gene therapy spending share by geography", "definition": "Percentage of cell and gene therapy spending attributable to a given geography." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 38, "value_text": "38%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Global cell and gene therapy spending and share by geography", "quote": "A majority (62%) of this spending is attributable to U.S. sales, compared to just 38% coming from other geographies.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNY", "bibtex": "@misc{iqvia2023cellkt7nny,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNY},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNV", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNV", "indicator": { "slug": "cell-and-gene-therapy-spending-year-over-year-growth", "name": "Cell and gene therapy spending year-over-year growth", "definition": "Percentage growth in cell and gene therapy spending versus the prior year." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 38, "value_text": "38%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Global cell and gene therapy spending and share by geography", "quote": "Spending grew by 38% in 2023 from the prior year, and spending has averaged 65% annual growth over the last five years as more products are reaching the market.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNV", "bibtex": "@misc{iqvia2023cellkt7nnv,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNV},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNG", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNG", "indicator": { "slug": "cell-and-gene-therapy-venture-capital-and-public-funding-deal-count", "name": "Cell and gene therapy venture capital and public funding deal count", "definition": "Number of venture capital and public funding transactions for cell and gene therapies in a given year." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true }, { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": false } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 100, "value_text": "nearly 100 deals", "unit": "count", "currency": null, "scale": "1", "value_type": "estimate", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Cell and gene therapy venture capital and public funding deal value in U.S.$$Mn and number of deals by type, 2014-2023", "quote": "Following historic funding levels in 2021 and a retraction in 2022, nearly 100 deals and $3.4Bn of deal value occurred in 2023.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNG", "bibtex": "@misc{iqvia2023cellkt7nng,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNG},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNJ", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNJ", "indicator": { "slug": "cell-and-gene-therapy-venture-capital-and-public-funding-deal-count", "name": "Cell and gene therapy venture capital and public funding deal count", "definition": "Number of venture capital and public funding transactions for cell and gene therapies in a given year." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true }, { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": false } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2021-01-01", "end": "2021-12-31", "type": "year" }, "value": 127, "value_text": "127", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Cell and gene therapy venture capital and public funding deal value in U.S.$$Mn and number of deals by type, 2014-2023", "quote": "The total number of deals peaked at 127 in 2021 — 57% higher than in 2020 — dropped 24% in 2022 to 97 deals, and remained flat in 2023 at 96 deals, although still up 19% from 2020.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2021). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNJ", "bibtex": "@misc{iqvia2021cellkt7nnj,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2021},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNJ},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNN", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNN", "indicator": { "slug": "cell-and-gene-therapy-venture-capital-and-public-funding-deal-count", "name": "Cell and gene therapy venture capital and public funding deal count", "definition": "Number of venture capital and public funding transactions for cell and gene therapies in a given year." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true }, { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": false } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2022-01-01", "end": "2022-12-31", "type": "year" }, "value": 97, "value_text": "97 deals", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Cell and gene therapy venture capital and public funding deal value in U.S.$$Mn and number of deals by type, 2014-2023", "quote": "The total number of deals peaked at 127 in 2021 — 57% higher than in 2020 — dropped 24% in 2022 to 97 deals, and remained flat in 2023 at 96 deals, although still up 19% from 2020.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2022). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNN", "bibtex": "@misc{iqvia2022cellkt7nnn,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2022},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNN},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNP", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNP", "indicator": { "slug": "cell-and-gene-therapy-venture-capital-and-public-funding-deal-count", "name": "Cell and gene therapy venture capital and public funding deal count", "definition": "Number of venture capital and public funding transactions for cell and gene therapies in a given year." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true }, { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": false } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 96, "value_text": "96 deals", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Cell and gene therapy venture capital and public funding deal value in U.S.$$Mn and number of deals by type, 2014-2023", "quote": "The total number of deals peaked at 127 in 2021 — 57% higher than in 2020 — dropped 24% in 2022 to 97 deals, and remained flat in 2023 at 96 deals, although still up 19% from 2020.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNP", "bibtex": "@misc{iqvia2023cellkt7nnp,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNP},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNH", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNH", "indicator": { "slug": "cell-and-gene-therapy-venture-capital-and-public-funding-deal-value", "name": "Cell and gene therapy venture capital and public funding deal value", "definition": "Total value of venture capital and public funding transactions for cell and gene therapies in a given year." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true }, { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": false } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 3.4, "value_text": "$3.4Bn", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Cell and gene therapy venture capital and public funding deal value in U.S.$$Mn and number of deals by type, 2014-2023", "quote": "Following historic funding levels in 2021 and a retraction in 2022, nearly 100 deals and $3.4Bn of deal value occurred in 2023.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNH", "bibtex": "@misc{iqvia2023cellkt7nnh,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNH},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNK", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNK", "indicator": { "slug": "cell-and-gene-therapy-venture-funding-deal-count-year-over-year-change", "name": "Cell and gene therapy venture funding deal count year-over-year change", "definition": "Percentage change in the number of cell and gene therapy venture capital and public funding deals versus the prior year." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2021-01-01", "end": "2021-12-31", "type": "year" }, "value": 57, "value_text": "57%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Cell and gene therapy venture capital and public funding deal value in U.S.$$Mn and number of deals by type, 2014-2023", "quote": "The total number of deals peaked at 127 in 2021 — 57% higher than in 2020 — dropped 24% in 2022 to 97 deals, and remained flat in 2023 at 96 deals, although still up 19% from 2020.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2021). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNK", "bibtex": "@misc{iqvia2021cellkt7nnk,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2021},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNK},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNM", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNM", "indicator": { "slug": "cell-and-gene-therapy-venture-funding-deal-count-year-over-year-change", "name": "Cell and gene therapy venture funding deal count year-over-year change", "definition": "Percentage change in the number of cell and gene therapy venture capital and public funding deals versus the prior year." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2022-01-01", "end": "2022-12-31", "type": "year" }, "value": -24, "value_text": "24%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Cell and gene therapy venture capital and public funding deal value in U.S.$$Mn and number of deals by type, 2014-2023", "quote": "The total number of deals peaked at 127 in 2021 — 57% higher than in 2020 — dropped 24% in 2022 to 97 deals, and remained flat in 2023 at 96 deals, although still up 19% from 2020.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2022). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNM", "bibtex": "@misc{iqvia2022cellkt7nnm,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2022},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNM},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNQ", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNQ", "indicator": { "slug": "cell-and-gene-therapy-venture-funding-deal-count-year-over-year-change", "name": "Cell and gene therapy venture funding deal count year-over-year change", "definition": "Percentage change in the number of cell and gene therapy venture capital and public funding deals versus the prior year." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 19, "value_text": "19%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Cell and gene therapy venture capital and public funding deal value in U.S.$$Mn and number of deals by type, 2014-2023", "quote": "The total number of deals peaked at 127 in 2021 — 57% higher than in 2020 — dropped 24% in 2022 to 97 deals, and remained flat in 2023 at 96 deals, although still up 19% from 2020.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNQ", "bibtex": "@misc{iqvia2023cellkt7nnq,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNQ},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_B0MJT3FDHN9S5XAPGB6GR93N6C", "url": "https://statorigin.org/stat/stat_B0MJT3FDHN9S5XAPGB6GR93N6C", "indicator": { "slug": "change-in-regional-share-of-global-clinical-trial-country-uses", "name": "Change in regional share of global clinical trial country uses", "definition": "Percentage change in a region's share of global clinical trial country uses between two periods." }, "industry": [ { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": true } ], "region": { "code": "EU", "name": "European Union", "type": "bloc" }, "period": { "start": "2019-01-01", "end": "2025-12-31", "type": "year" }, "value": -17, "value_text": "17%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025", "document_type": "press_release", "locator": "Exhibit 55: Country utilization as percentage of global trial country uses, 2019 and 2025", "quote": "Although Western Europe remained the most-utilized region in 2025, with a 27% share of global country uses, its utilization fell by 17% in comparison to 2019.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T01:20:11.850Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Via StatOrigin, https://statorigin.org/stat/stat_B0MJT3FDHN9S5XAPGB6GR93N6C", "bibtex": "@misc{iqvia2025changer93n6c,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_B0MJT3FDHN9S5XAPGB6GR93N6C},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T01:20:11.850Z" }, { "id": "stat_SQ9DS6RADFJ9ZQ90GXV1Z50C0B", "url": "https://statorigin.org/stat/stat_SQ9DS6RADFJ9ZQ90GXV1Z50C0B", "indicator": { "slug": "change-in-regional-share-of-global-clinical-trial-country-uses", "name": "Change in regional share of global clinical trial country uses", "definition": "Percentage change in a region's share of global clinical trial country uses between two periods." }, "industry": [ { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": true } ], "region": { "code": "EU", "name": "European Union", "type": "bloc" }, "period": { "start": "2019-01-01", "end": "2025-12-31", "type": "year" }, "value": -17, "value_text": "17%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026", "document_type": "press_release", "locator": "Exhibit 55: Country utilization as percentage of global trial country uses, 2019 and 2025", "quote": "Although Western Europe remained the most-utilized region in 2025, with a 27% share of global country uses, its utilization fell by 17% in comparison to 2019.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T01:20:11.850Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_SQ9DS6RADFJ9ZQ90GXV1Z50C0B", "bibtex": "@misc{iqvia2025changez50c0b,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_SQ9DS6RADFJ9ZQ90GXV1Z50C0B},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T01:20:11.850Z" }, { "id": "stat_1D4B4KPDFK0WHBM8D327B6EW89", "url": "https://statorigin.org/stat/stat_1D4B4KPDFK0WHBM8D327B6EW89", "indicator": { "slug": "change-in-regional-share-of-global-clinical-trial-country-uses", "name": "Change in regional share of global clinical trial country uses", "definition": "Percentage change in a region's share of global clinical trial country uses between two periods." }, "industry": [ { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": true } ], "region": { "code": "EU", "name": "European Union", "type": "bloc" }, "period": { "start": "2019-01-01", "end": "2023-12-31", "type": "year" }, "value": 21, "value_text": "21%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Key findings", "quote": "Country utilization by region has shifted significantly in the past five years with Western Europe share declining by 21% (from 32% to 25% of global total) and Eastern Europe share decreasing 33% (from 17% to 11%), as North America share increased 17% (from 19% to 23%) and China share increased 57% (from 10% to 15%).", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T01:20:11.850Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_1D4B4KPDFK0WHBM8D327B6EW89", "bibtex": "@misc{iqvia2023changeb6ew89,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_1D4B4KPDFK0WHBM8D327B6EW89},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T01:20:11.850Z" }, { "id": "stat_2J0Y2WA7Z6ZFJ8RAPE1DA2HPC9", "url": "https://statorigin.org/stat/stat_2J0Y2WA7Z6ZFJ8RAPE1DA2HPC9", "indicator": { "slug": "change-in-regional-share-of-global-clinical-trial-country-uses", "name": "Change in regional share of global clinical trial country uses", "definition": "Percentage change in a region's share of global clinical trial country uses between two periods." }, "industry": [ { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": true } ], "region": { "code": "NAMERICA", "name": "North America", "type": "bloc" }, "period": { "start": "2019-01-01", "end": "2023-12-31", "type": "year" }, "value": 17, "value_text": "17%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Key findings", "quote": "Country utilization by region has shifted significantly in the past five years with Western Europe share declining by 21% (from 32% to 25% of global total) and Eastern Europe share decreasing 33% (from 17% to 11%), as North America share increased 17% (from 19% to 23%) and China share increased 57% (from 10% to 15%).", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T01:20:11.850Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_2J0Y2WA7Z6ZFJ8RAPE1DA2HPC9", "bibtex": "@misc{iqvia2023changea2hpc9,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_2J0Y2WA7Z6ZFJ8RAPE1DA2HPC9},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T01:20:11.850Z" }, { "id": "stat_1AFNYY5PNGTNY3YMMFH8ANZV62", "url": "https://statorigin.org/stat/stat_1AFNYY5PNGTNY3YMMFH8ANZV62", "indicator": { "slug": "change-in-regional-share-of-global-clinical-trial-country-uses", "name": "Change in regional share of global clinical trial country uses", "definition": "Percentage change in a region's share of global clinical trial country uses between two periods." }, "industry": [ { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2019-01-01", "end": "2023-12-31", "type": "year" }, "value": 57, "value_text": "57%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Key findings", "quote": "Country utilization by region has shifted significantly in the past five years with Western Europe share declining by 21% (from 32% to 25% of global total) and Eastern Europe share decreasing 33% (from 17% to 11%), as North America share increased 17% (from 19% to 23%) and China share increased 57% (from 10% to 15%).", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T01:20:11.850Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_1AFNYY5PNGTNY3YMMFH8ANZV62", "bibtex": "@misc{iqvia2023changeanzv62,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_1AFNYY5PNGTNY3YMMFH8ANZV62},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T01:20:11.850Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NPE", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPE", "indicator": { "slug": "clinical-trial-country-use-share", "name": "Clinical trial country use share", "definition": "Percentage of total clinical trial country uses accounted for by a given region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "EU", "name": "European Union", "type": "bloc" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 27, "value_text": "27%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025", "document_type": "press_release", "locator": "Exhibit 55: Country utilization as percentage of global trial country uses, 2019 and 2025", "quote": "Although Western Europe remained the most-utilized region in 2025, with a 27% share of global country uses, its utilization fell by 17% in comparison to 2019.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPE", "bibtex": "@misc{iqvia2025clinicalkt7npe,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPE},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGCJ", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCJ", "indicator": { "slug": "clinical-trial-country-use-share", "name": "Clinical trial country use share", "definition": "Percentage of total clinical trial country uses accounted for by a given region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "EU", "name": "European Union", "type": "bloc" }, "period": { "start": "2019-01-01", "end": "2019-12-31", "type": "year" }, "value": 32, "value_text": "32%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Key findings:", "quote": "Country utilization by region has shifted significantly in the past five years with Western Europe share declining by 21% (from 32% to 25% of global total) and Eastern Europe share decreasing 33% (from 17% to 11%), as North America share increased 17% (from 19% to 23%) and China share increased 57% (from 10% to 15%).", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2019). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCJ", "bibtex": "@misc{iqvia2019clinicalbjmgcj,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2019},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCJ},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGCK", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCK", "indicator": { "slug": "clinical-trial-country-use-share", "name": "Clinical trial country use share", "definition": "Percentage of total clinical trial country uses accounted for by a given region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "EU", "name": "European Union", "type": "bloc" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 25, "value_text": "25%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Key findings:", "quote": "Country utilization by region has shifted significantly in the past five years with Western Europe share declining by 21% (from 32% to 25% of global total) and Eastern Europe share decreasing 33% (from 17% to 11%), as North America share increased 17% (from 19% to 23%) and China share increased 57% (from 10% to 15%).", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCK", "bibtex": "@misc{iqvia2023clinicalbjmgck,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCK},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGCN", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCN", "indicator": { "slug": "clinical-trial-country-use-share", "name": "Clinical trial country use share", "definition": "Percentage of total clinical trial country uses accounted for by a given region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "NAMERICA", "name": "North America", "type": "bloc" }, "period": { "start": "2019-01-01", "end": "2019-12-31", "type": "year" }, "value": 19, "value_text": "19%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Key findings:", "quote": "Country utilization by region has shifted significantly in the past five years with Western Europe share declining by 21% (from 32% to 25% of global total) and Eastern Europe share decreasing 33% (from 17% to 11%), as North America share increased 17% (from 19% to 23%) and China share increased 57% (from 10% to 15%).", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2019). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCN", "bibtex": "@misc{iqvia2019clinicalbjmgcn,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2019},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCN},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGCP", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCP", "indicator": { "slug": "clinical-trial-country-use-share", "name": "Clinical trial country use share", "definition": "Percentage of total clinical trial country uses accounted for by a given region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "NAMERICA", "name": "North America", "type": "bloc" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 23, "value_text": "23%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Key findings:", "quote": "Country utilization by region has shifted significantly in the past five years with Western Europe share declining by 21% (from 32% to 25% of global total) and Eastern Europe share decreasing 33% (from 17% to 11%), as North America share increased 17% (from 19% to 23%) and China share increased 57% (from 10% to 15%).", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCP", "bibtex": "@misc{iqvia2023clinicalbjmgcp,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCP},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGCR", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCR", "indicator": { "slug": "clinical-trial-country-use-share", "name": "Clinical trial country use share", "definition": "Percentage of total clinical trial country uses accounted for by a given region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2019-01-01", "end": "2019-12-31", "type": "year" }, "value": 10, "value_text": "10%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Key findings:", "quote": "Country utilization by region has shifted significantly in the past five years with Western Europe share declining by 21% (from 32% to 25% of global total) and Eastern Europe share decreasing 33% (from 17% to 11%), as North America share increased 17% (from 19% to 23%) and China share increased 57% (from 10% to 15%).", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2019). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCR", "bibtex": "@misc{iqvia2019clinicalbjmgcr,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2019},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCR},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGCS", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCS", "indicator": { "slug": "clinical-trial-country-use-share", "name": "Clinical trial country use share", "definition": "Percentage of total clinical trial country uses accounted for by a given region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 15, "value_text": "15%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Key findings:", "quote": "Country utilization by region has shifted significantly in the past five years with Western Europe share declining by 21% (from 32% to 25% of global total) and Eastern Europe share decreasing 33% (from 17% to 11%), as North America share increased 17% (from 19% to 23%) and China share increased 57% (from 10% to 15%).", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCS", "bibtex": "@misc{iqvia2023clinicalbjmgcs,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCS},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGCT", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCT", "indicator": { "slug": "clinical-trial-country-use-share", "name": "Clinical trial country use share", "definition": "Percentage of total clinical trial country uses accounted for by a given region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2021-01-01", "end": "2023-12-31", "type": "year" }, "value": 16, "value_text": "16%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Country utilization is heavily consolidated in U.S., China and Western European countries", "quote": "The top 10 most used countries account for 58% of the total average pipeline country use, with the United States and China responsible for 16% and 13%, respectively, of total country-uses for trials started in the 2021–2023 timeframe.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCT", "bibtex": "@misc{iqvia2023clinicalbjmgct,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCT},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGCV", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCV", "indicator": { "slug": "clinical-trial-country-use-share", "name": "Clinical trial country use share", "definition": "Percentage of total clinical trial country uses accounted for by a given region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2021-01-01", "end": "2023-12-31", "type": "year" }, "value": 13, "value_text": "13%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Country utilization is heavily consolidated in U.S., China and Western European countries", "quote": "The top 10 most used countries account for 58% of the total average pipeline country use, with the United States and China responsible for 16% and 13%, respectively, of total country-uses for trials started in the 2021–2023 timeframe.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCV", "bibtex": "@misc{iqvia2023clinicalbjmgcv,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCV},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_27RXMK6HGBJ65R9TNAMSBH4MKK", "url": "https://statorigin.org/stat/stat_27RXMK6HGBJ65R9TNAMSBH4MKK", "indicator": { "slug": "clinical-trial-country-use-share", "name": "Clinical trial country use share", "definition": "Percentage of total clinical trial country uses accounted for by a given region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "EU", "name": "European Union", "type": "bloc" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 27, "value_text": "27%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026", "document_type": "press_release", "locator": "Exhibit 55: Country utilization as percentage of global trial country uses, 2019 and 2025", "quote": "Although Western Europe remained the most-utilized region in 2025, with a 27% share of global country uses, its utilization fell by 17% in comparison to 2019.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_27RXMK6HGBJ65R9TNAMSBH4MKK", "bibtex": "@misc{iqvia2025clinicalbh4mkk,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_27RXMK6HGBJ65R9TNAMSBH4MKK},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGCH", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCH", "indicator": { "slug": "clinical-trial-country-use-share-change", "name": "Clinical trial country use share change", "definition": "Relative percentage change in a region's share of total clinical trial country uses over a comparison period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "EU", "name": "European Union", "type": "bloc" }, "period": { "start": "2019-01-01", "end": "2023-12-31", "type": "year" }, "value": -21, "value_text": "21%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Key findings:", "quote": "Country utilization by region has shifted significantly in the past five years with Western Europe share declining by 21% (from 32% to 25% of global total) and Eastern Europe share decreasing 33% (from 17% to 11%), as North America share increased 17% (from 19% to 23%) and China share increased 57% (from 10% to 15%).", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCH", "bibtex": "@misc{iqvia2023clinicalbjmgch,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCH},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGCM", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCM", "indicator": { "slug": "clinical-trial-country-use-share-change", "name": "Clinical trial country use share change", "definition": "Relative percentage change in a region's share of total clinical trial country uses over a comparison period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "NAMERICA", "name": "North America", "type": "bloc" }, "period": { "start": "2019-01-01", "end": "2023-12-31", "type": "year" }, "value": 17, "value_text": "17%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Key findings:", "quote": "Country utilization by region has shifted significantly in the past five years with Western Europe share declining by 21% (from 32% to 25% of global total) and Eastern Europe share decreasing 33% (from 17% to 11%), as North America share increased 17% (from 19% to 23%) and China share increased 57% (from 10% to 15%).", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCM", "bibtex": "@misc{iqvia2023clinicalbjmgcm,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCM},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGCQ", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCQ", "indicator": { "slug": "clinical-trial-country-use-share-change", "name": "Clinical trial country use share change", "definition": "Relative percentage change in a region's share of total clinical trial country uses over a comparison period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2019-01-01", "end": "2023-12-31", "type": "year" }, "value": 57, "value_text": "57%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Key findings:", "quote": "Country utilization by region has shifted significantly in the past five years with Western Europe share declining by 21% (from 32% to 25% of global total) and Eastern Europe share decreasing 33% (from 17% to 11%), as North America share increased 17% (from 19% to 23%) and China share increased 57% (from 10% to 15%).", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCQ", "bibtex": "@misc{iqvia2023clinicalbjmgcq,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCQ},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NPF", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPF", "indicator": { "slug": "clinical-trial-country-uses-growth-rate", "name": "Clinical trial country uses growth rate", "definition": "Percentage change in clinical trial country uses over time." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "EU", "name": "European Union", "type": "bloc" }, "period": { "start": "2019-01-01", "end": "2025-12-31", "type": "year" }, "value": -17, "value_text": "17%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025", "document_type": "press_release", "locator": "Exhibit 55: Country utilization as percentage of global trial country uses, 2019 and 2025", "quote": "Although Western Europe remained the most-utilized region in 2025, with a 27% share of global country uses, its utilization fell by 17% in comparison to 2019.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPF", "bibtex": "@misc{iqvia2025clinicalkt7npf,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPF},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_7AQD6KN4AZXA47Z3V9ANMTEE60", "url": "https://statorigin.org/stat/stat_7AQD6KN4AZXA47Z3V9ANMTEE60", "indicator": { "slug": "clinical-trial-country-utilization-growth-rate", "name": "Clinical trial country utilization growth rate", "definition": "Percentage change in clinical trial country uses over a specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "EU", "name": "European Union", "type": "bloc" }, "period": { "start": "2019-01-01", "end": "2025-12-31", "type": "year" }, "value": -17, "value_text": "17%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026", "document_type": "press_release", "locator": "Exhibit 55: Country utilization as percentage of global trial country uses, 2019 and 2025", "quote": "Although Western Europe remained the most-utilized region in 2025, with a 27% share of global country uses, its utilization fell by 17% in comparison to 2019.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_7AQD6KN4AZXA47Z3V9ANMTEE60", "bibtex": "@misc{iqvia2025clinicalmtee60,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_7AQD6KN4AZXA47Z3V9ANMTEE60},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGCG", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCG", "indicator": { "slug": "clinical-trial-enrollment-duration-growth", "name": "Clinical trial enrollment duration growth", "definition": "Percentage increase in clinical trial enrollment duration from trial start to the end of enrollment across all phases." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2019-01-01", "end": "2023-12-31", "type": "year" }, "value": 26, "value_text": "26%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Key findings:", "quote": "Clinical trial enrollment duration has been increasing over the past five years, and the time from trial start to the end of enrollment has increased by 26% across all phases.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCG", "bibtex": "@misc{iqvia2023clinicalbjmgcg,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCG},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_W1ZDXQTWJP5RTE374DGHEHPYBK", "url": "https://statorigin.org/stat/stat_W1ZDXQTWJP5RTE374DGHEHPYBK", "indicator": { "slug": "clinical-trial-enrollment-duration-increase", "name": "Clinical trial enrollment duration increase", "definition": "Percentage increase in the time from clinical trial start to end of enrollment across all trial phases, comparing periods." }, "industry": [ { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2019-01-01", "end": "2023-12-31", "type": "year" }, "value": 26, "value_text": "26%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Key findings", "quote": "Clinical trial enrollment duration has been increasing over the past five years, and the time from trial start to the end of enrollment has increased by 26% across all phases.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T01:20:11.850Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_W1ZDXQTWJP5RTE374DGHEHPYBK", "bibtex": "@misc{iqvia2023clinicalehpybk,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_W1ZDXQTWJP5RTE374DGHEHPYBK},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T01:20:11.850Z" }, { "id": "stat_ZY7JN7XSG36DTPPH1BM1W9V7TG", "url": "https://statorigin.org/stat/stat_ZY7JN7XSG36DTPPH1BM1W9V7TG", "indicator": { "slug": "clinical-trial-enrollment-duration-increase-multi-year-total", "name": "Clinical trial enrollment duration increase (multi-year total)", "definition": "Average increase in clinical trial enrollment duration measured in months." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2019-01-01", "end": "2023-12-31", "type": "year" }, "value": 6, "value_text": "six months", "unit": "months", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Enrollment is taking longer across all phases of development", "quote": "Phase II and Phase III saw 23% and 16% increases, respectively, with Phase II enrollment times increasing by an average of six months over the five-year timeframe.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_ZY7JN7XSG36DTPPH1BM1W9V7TG", "bibtex": "@misc{iqvia2023clinicalw9v7tg,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_ZY7JN7XSG36DTPPH1BM1W9V7TG},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_0ZN6HK2VP8CD4DNEMD29W75C86", "url": "https://statorigin.org/stat/stat_0ZN6HK2VP8CD4DNEMD29W75C86", "indicator": { "slug": "commercial-insurance-out-of-pocket-cost-growth", "name": "Commercial insurance out-of-pocket cost growth", "definition": "Year-over-year aggregate percentage growth in commercial insurance patient out-of-pocket medicine costs." }, "industry": [ { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 5, "value_text": "5%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "Commercial insurance out‑of‑pocket costs, which account for 52% of total patient out‑of‑pocket costs, rose 5% in aggregate in 2025 and 37% over five years due to increased volume and a shift towards higher‑cost prescriptions.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T01:20:11.850Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_0ZN6HK2VP8CD4DNEMD29W75C86", "bibtex": "@misc{iqvia2025commercialw75c86,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_0ZN6HK2VP8CD4DNEMD29W75C86},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T01:20:11.850Z" }, { "id": "stat_JNV9T4G7XKM6JDNTGS7TE1BNKD", "url": "https://statorigin.org/stat/stat_JNV9T4G7XKM6JDNTGS7TE1BNKD", "indicator": { "slug": "commercial-insurance-out-of-pocket-cost-growth-5-year", "name": "Commercial insurance out-of-pocket cost growth (5-year)", "definition": "Aggregate percentage growth in commercial insurance patient out-of-pocket medicine costs over the preceding five years." }, "industry": [ { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2021-01-01", "end": "2025-12-31", "type": "year" }, "value": 37, "value_text": "37%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "Commercial insurance out‑of‑pocket costs, which account for 52% of total patient out‑of‑pocket costs, rose 5% in aggregate in 2025 and 37% over five years due to increased volume and a shift towards higher‑cost prescriptions.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T01:20:11.850Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_JNV9T4G7XKM6JDNTGS7TE1BNKD", "bibtex": "@misc{iqvia2025commerciale1bnkd,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_JNV9T4G7XKM6JDNTGS7TE1BNKD},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T01:20:11.850Z" }, { "id": "stat_H7DPFVJGXQAMKZ92F3CWG9K3Y4", "url": "https://statorigin.org/stat/stat_H7DPFVJGXQAMKZ92F3CWG9K3Y4", "indicator": { "slug": "commercial-insurance-patient-out-of-pocket-medicine-cost-growth-rate", "name": "Commercial insurance patient out-of-pocket medicine cost growth rate", "definition": "Annual percentage growth in aggregate out-of-pocket medicine spending for commercially insured patients." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 5, "value_text": "5%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "Commercial insurance out‑of‑pocket costs, which account for 52% of total patient out‑of‑pocket costs, rose 5% in aggregate in 2025 and 37% over five years due to increased volume and a shift towards higher‑cost prescriptions.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_H7DPFVJGXQAMKZ92F3CWG9K3Y4", "bibtex": "@misc{iqvia2025commercialg9k3y4,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_H7DPFVJGXQAMKZ92F3CWG9K3Y4},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_SXCAHHYCQ12XXT8NCDXKATWBAT", "url": "https://statorigin.org/stat/stat_SXCAHHYCQ12XXT8NCDXKATWBAT", "indicator": { "slug": "commercial-insurance-share-of-patient-out-of-pocket-costs", "name": "Commercial insurance share of patient out-of-pocket costs", "definition": "Share of total patient out-of-pocket medicine costs attributable to commercially insured patients." }, "industry": [ { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 52, "value_text": "52%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "Commercial insurance out‑of‑pocket costs, which account for 52% of total patient out‑of‑pocket costs, rose 5% in aggregate in 2025 and 37% over five years due to increased volume and a shift towards higher‑cost prescriptions.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T01:20:11.850Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_SXCAHHYCQ12XXT8NCDXKATWBAT", "bibtex": "@misc{iqvia2025commercialatwbat,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_SXCAHHYCQ12XXT8NCDXKATWBAT},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T01:20:11.850Z" }, { "id": "stat_P27F75WTH77JYT1XF5RQ253JYM", "url": "https://statorigin.org/stat/stat_P27F75WTH77JYT1XF5RQ253JYM", "indicator": { "slug": "commercial-insurance-share-of-patient-out-of-pocket-medicine-costs", "name": "Commercial insurance share of patient out-of-pocket medicine costs", "definition": "Share of total patient out-of-pocket medicine costs accounted for by commercially insured patients." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 52, "value_text": "52%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "Commercial insurance out‑of‑pocket costs, which account for 52% of total patient out‑of‑pocket costs, rose 5% in aggregate in 2025 and 37% over five years due to increased volume and a shift towards higher‑cost prescriptions.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_P27F75WTH77JYT1XF5RQ253JYM", "bibtex": "@misc{iqvia2025commercial253jym,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_P27F75WTH77JYT1XF5RQ253JYM},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NMX", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMX", "indicator": { "slug": "compound-annual-net-medicine-spending-growth", "name": "Compound annual net medicine spending growth", "definition": "Average annual growth rate of medicine spending at net prices over a five-year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2020-01-01", "end": "2025-12-31", "type": "year" }, "value": 9.3, "value_text": "9.3%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Key Findings", "quote": "The U.S. market at net prices grew 10.6% in 2025 and an average of 9.3% annually over the last five years", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMX", "bibtex": "@misc{iqvia2025compoundkt7nmx,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMX},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_RA1PH1KQTKGZAGX5BDGPRFDSMP", "url": "https://statorigin.org/stat/stat_RA1PH1KQTKGZAGX5BDGPRFDSMP", "indicator": { "slug": "countries-excluding-u-s-driving-global-pharmaceutical-spending-growth", "name": "Countries (excluding U.S.) driving global pharmaceutical spending growth", "definition": "Number of countries, other than the U.S., accounting for the majority of global pharmaceutical spending growth through 2030." }, "industry": [ { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2025-01-01", "end": "2030-12-31", "type": "year" }, "value": 14, "value_text": "14 other countries", "unit": "count", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-medicine-use-trends-2026", "document_type": "press_release", "locator": "Exhibit 19: Global spending and growth, excluding COVID-19 vaccines and therapeutics,constant $USBn, 2020–2030", "quote": "The U.S. and 14 other countries account for 76% of global growth through 2030.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T01:20:11.850Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2030). Global Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_RA1PH1KQTKGZAGX5BDGPRFDSMP", "bibtex": "@misc{iqvia2030countriesrfdsmp,\n author = {{IQVIA Institute}},\n title = {Global Medicine Use Trends 2026},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_RA1PH1KQTKGZAGX5BDGPRFDSMP},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T01:20:11.850Z" }, { "id": "stat_MKSSJ11HJT01770TDNK75774X1", "url": "https://statorigin.org/stat/stat_MKSSJ11HJT01770TDNK75774X1", "indicator": { "slug": "country-share-of-clinical-trial-country-uses", "name": "Country share of clinical trial country-uses", "definition": "A given country's share of total clinical trial country-uses for trials started in a stated period." }, "industry": [ { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2021-01-01", "end": "2023-12-31", "type": "year" }, "value": 16, "value_text": "16%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Country utilization is heavily consolidated in U.S., China and Western European countries", "quote": "The top 10 most used countries account for 58% of the total average pipeline country use, with the United States and China responsible for 16% and 13%, respectively, of total country-uses for trials started in the 2021–2023 timeframe.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T01:20:11.850Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_MKSSJ11HJT01770TDNK75774X1", "bibtex": "@misc{iqvia2023country5774x1,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_MKSSJ11HJT01770TDNK75774X1},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T01:20:11.850Z" }, { "id": "stat_4399GQKJSXEDYAQPDPEPN2PRHW", "url": "https://statorigin.org/stat/stat_4399GQKJSXEDYAQPDPEPN2PRHW", "indicator": { "slug": "country-share-of-clinical-trial-country-uses", "name": "Country share of clinical trial country-uses", "definition": "A given country's share of total clinical trial country-uses for trials started in a stated period." }, "industry": [ { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2021-01-01", "end": "2023-12-31", "type": "year" }, "value": 13, "value_text": "13%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Country utilization is heavily consolidated in U.S., China and Western European countries", "quote": "The top 10 most used countries account for 58% of the total average pipeline country use, with the United States and China responsible for 16% and 13%, respectively, of total country-uses for trials started in the 2021–2023 timeframe.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T01:20:11.850Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_4399GQKJSXEDYAQPDPEPN2PRHW", "bibtex": "@misc{iqvia2023countryn2prhw,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_4399GQKJSXEDYAQPDPEPN2PRHW},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T01:20:11.850Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NND", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NND", "indicator": { "slug": "cumulative-cell-and-gene-therapy-launches", "name": "Cumulative cell and gene therapy launches", "definition": "Total number of cell and gene therapies launched commercially to date." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-12-31", "end": "2023-12-31", "type": "point" }, "value": 76, "value_text": "76", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Key findings", "quote": "As of the end of 2023, 76 cell and gene therapies have been launched globally, more than double the number of therapies that had been launched by 2013.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NND", "bibtex": "@misc{iqvia2023cumulativekt7nnd,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NND},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NP6", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NP6", "indicator": { "slug": "cumulative-five-year-novel-active-substance-launches", "name": "Cumulative five-year novel active substance launches", "definition": "Total cumulative number of novel active substances launched over a five-year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2021-01-01", "end": "2025-12-31", "type": "year" }, "value": 388, "value_text": "388", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025", "document_type": "press_release", "locator": "Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025", "quote": "The 79 novel active substances launched globally in 2025 bring the five-year total to 388, or 369 excluding COVID-19 vaccines and therapeutics.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NP6", "bibtex": "@misc{iqvia2025cumulativekt7np6,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NP6},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NPC", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPC", "indicator": { "slug": "cumulative-five-year-novel-active-substance-launches", "name": "Cumulative five-year novel active substance launches", "definition": "Total cumulative number of novel active substances launched over a five-year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2021-01-01", "end": "2025-12-31", "type": "year" }, "value": 270, "value_text": "270", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025", "document_type": "press_release", "locator": "Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025", "quote": "A total of 53 NAS launched in the U.S. in 2025, bringing the five-year total to 270.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPC", "bibtex": "@misc{iqvia2025cumulativekt7npc,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPC},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGD2", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD2", "indicator": { "slug": "cumulative-five-year-novel-active-substance-launches", "name": "Cumulative five-year novel active substance launches", "definition": "Total cumulative number of novel active substances launched over a five-year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2021-01-01", "end": "2025-12-31", "type": "year" }, "value": 388, "value_text": "388", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026", "document_type": "press_release", "locator": "Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025", "quote": "The 79 novel active substances launched globally in 2025 bring the five-year total to 388, or 369 excluding COVID-19 vaccines and therapeutics.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD2", "bibtex": "@misc{iqvia2025cumulativebjmgd2,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD2},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGD7", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD7", "indicator": { "slug": "cumulative-five-year-novel-active-substance-launches", "name": "Cumulative five-year novel active substance launches", "definition": "Total cumulative number of novel active substances launched over a five-year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2021-01-01", "end": "2025-12-31", "type": "year" }, "value": 270, "value_text": "270", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026", "document_type": "press_release", "locator": "Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025", "quote": "A total of 53 NAS launched in the U.S. in 2025, bringing the five-year total to 270.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD7", "bibtex": "@misc{iqvia2025cumulativebjmgd7,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD7},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGD3", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD3", "indicator": { "slug": "cumulative-five-year-novel-active-substance-launches-excluding-covid-19-vaccines", "name": "Cumulative five-year novel active substance launches excluding COVID-19 vaccines and therapeutics", "definition": "Total cumulative number of novel active substances launched over a five-year period, excluding COVID-19 vaccines and therapeutics." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2021-01-01", "end": "2025-12-31", "type": "year" }, "value": 369, "value_text": "369", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026", "document_type": "press_release", "locator": "Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025", "quote": "The 79 novel active substances launched globally in 2025 bring the five-year total to 388, or 369 excluding COVID-19 vaccines and therapeutics.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD3", "bibtex": "@misc{iqvia2025cumulativebjmgd3,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD3},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_NYSKWRYCP3H5S0110S5GC4FXVX", "url": "https://statorigin.org/stat/stat_NYSKWRYCP3H5S0110S5GC4FXVX", "indicator": { "slug": "cumulative-oncology-novel-active-substance-launches", "name": "Cumulative oncology novel active substance launches", "definition": "Cumulative number of oncology novel active substances launched over a specified multi-year timeframe." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2020-01-01", "end": "2024-12-31", "type": "year" }, "value": 132, "value_text": "132", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global Oncology Trends 2025", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025", "document_type": "press_release", "locator": "Key Findings: Oncology continues to see significant novel medicine launches", "quote": "A total of 132 oncology NAS have launched globally in the past five years and 282 over 20 years with large geographic variations, including a notable acceleration in launches in China since 2019", "published_date": null, "accessed_at": "2026-09-16", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2024). Global Oncology Trends 2025. Retrieved September 16, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Via StatOrigin, https://statorigin.org/stat/stat_NYSKWRYCP3H5S0110S5GC4FXVX", "bibtex": "@misc{iqvia2024cumulativec4fxvx,\n author = {{IQVIA Institute}},\n title = {Global Oncology Trends 2025},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_NYSKWRYCP3H5S0110S5GC4FXVX},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Accessed September 16, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_J9A48R3R2F01ABKWSC1MHS4RM4", "url": "https://statorigin.org/stat/stat_J9A48R3R2F01ABKWSC1MHS4RM4", "indicator": { "slug": "cumulative-oncology-novel-active-substance-launches", "name": "Cumulative oncology novel active substance launches", "definition": "Cumulative number of oncology novel active substances launched over a specified multi-year timeframe." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2005-01-01", "end": "2024-12-31", "type": "year" }, "value": 282, "value_text": "282", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global Oncology Trends 2025", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025", "document_type": "press_release", "locator": "Key Findings: Oncology continues to see significant novel medicine launches", "quote": "A total of 132 oncology NAS have launched globally in the past five years and 282 over 20 years with large geographic variations, including a notable acceleration in launches in China since 2019", "published_date": null, "accessed_at": "2026-09-16", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2024). Global Oncology Trends 2025. Retrieved September 16, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Via StatOrigin, https://statorigin.org/stat/stat_J9A48R3R2F01ABKWSC1MHS4RM4", "bibtex": "@misc{iqvia2024cumulativehs4rm4,\n author = {{IQVIA Institute}},\n title = {Global Oncology Trends 2025},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_J9A48R3R2F01ABKWSC1MHS4RM4},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Accessed September 16, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_Q9A5M6BZ1GWQE1K2KTE3DPWSX5", "url": "https://statorigin.org/stat/stat_Q9A5M6BZ1GWQE1K2KTE3DPWSX5", "indicator": { "slug": "cumulative-oncology-novel-active-substance-launches", "name": "Cumulative oncology novel active substance launches", "definition": "Cumulative number of oncology novel active substances launched over a specified multi-year timeframe." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2015-01-01", "end": "2019-12-31", "type": "year" }, "value": 79, "value_text": "79", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global Oncology Trends 2025", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025", "document_type": "press_release", "locator": "Other Findings", "quote": "Globally there were 132 oncology NAS launched in the past five years, up from 79 in the prior five years, while the number of launches by key geographies shifted considerably.", "published_date": null, "accessed_at": "2026-09-16", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2019). Global Oncology Trends 2025. Retrieved September 16, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Via StatOrigin, https://statorigin.org/stat/stat_Q9A5M6BZ1GWQE1K2KTE3DPWSX5", "bibtex": "@misc{iqvia2019cumulativedpwsx5,\n author = {{IQVIA Institute}},\n title = {Global Oncology Trends 2025},\n year = {2019},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_Q9A5M6BZ1GWQE1K2KTE3DPWSX5},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Accessed September 16, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_WHJ9R2JH2WSB7MBQ2VB2PKTEJ8", "url": "https://statorigin.org/stat/stat_WHJ9R2JH2WSB7MBQ2VB2PKTEJ8", "indicator": { "slug": "domestic-only-oncology-nas-launches-cumulative", "name": "Domestic-only oncology NAS launches (cumulative)", "definition": "Number of oncology novel active substances launched only in their domestic market, with no launch in other markets, over a stated period." }, "industry": [ { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2020-01-01", "end": "2024-12-31", "type": "year" }, "value": 45, "value_text": "45", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global Oncology Trends 2025", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025", "document_type": "press_release", "locator": "Other Findings", "quote": "Notably, China had 45 NAS in the past five years that have not launched in other markets to date, beginning a pattern of domestic-first or domestic-only innovation not previously seen.", "published_date": null, "accessed_at": "2026-09-16", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T01:20:11.850Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2024). Global Oncology Trends 2025. Retrieved September 16, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Via StatOrigin, https://statorigin.org/stat/stat_WHJ9R2JH2WSB7MBQ2VB2PKTEJ8", "bibtex": "@misc{iqvia2024domesticpktej8,\n author = {{IQVIA Institute}},\n title = {Global Oncology Trends 2025},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_WHJ9R2JH2WSB7MBQ2VB2PKTEJ8},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Accessed September 16, 2026.}\n}" }, "updated_at": "2026-09-17T01:20:11.850Z" }, { "id": "stat_JJDK21XPDT22P38QF7T8WQ0QXK", "url": "https://statorigin.org/stat/stat_JJDK21XPDT22P38QF7T8WQ0QXK", "indicator": { "slug": "domestic-only-oncology-novel-active-substance-launches-multi-year-total", "name": "Domestic-only oncology novel active substance launches (multi-year total)", "definition": "Number of oncology novel active substances launched exclusively within a single domestic market without rollouts in other jurisdictions." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2020-01-01", "end": "2024-12-31", "type": "year" }, "value": 45, "value_text": "45", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global Oncology Trends 2025", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025", "document_type": "press_release", "locator": "Other Findings", "quote": "Notably, China had 45 NAS in the past five years that have not launched in other markets to date, beginning a pattern of domestic-first or domestic-only innovation not previously seen.", "published_date": null, "accessed_at": "2026-09-16", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2024). Global Oncology Trends 2025. Retrieved September 16, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Via StatOrigin, https://statorigin.org/stat/stat_JJDK21XPDT22P38QF7T8WQ0QXK", "bibtex": "@misc{iqvia2024domesticwq0qxk,\n author = {{IQVIA Institute}},\n title = {Global Oncology Trends 2025},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_JJDK21XPDT22P38QF7T8WQ0QXK},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Accessed September 16, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNB", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNB", "indicator": { "slug": "expected-annual-novel-active-substance-launches-lower-bound", "name": "Expected annual novel active substance launches (lower bound)", "definition": "Lower bound of the projected average annual number of novel active substance launches over the next five years." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-01-01", "end": "2030-12-31", "type": "year" }, "value": 50, "value_text": "50", "unit": "count", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "Growth will be driven by the adoption of newly launched innovative products, with an average of 50–55 new medicines expected to launch annually over the next five years, including therapies in oncology, immunology, and other specialty areas, as well as more traditional treatments in diabetes, obesity, and neurology.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2030). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNB", "bibtex": "@misc{iqvia2030expectedkt7nnb,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNB},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NP7", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NP7", "indicator": { "slug": "expected-annual-novel-active-substance-launches-lower-bound", "name": "Expected annual novel active substance launches (lower bound)", "definition": "Lower bound of the projected average annual number of novel active substance launches over the next five years." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2030-12-31", "type": "year" }, "value": 70, "value_text": "70", "unit": "count", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025", "document_type": "press_release", "locator": "Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025", "quote": "Based on molecules in the late-stage pipeline and historic success rates, over the next five years an average of 70–80 NAS are expected to launch annually, expanding the number of NAS launched globally by 350–400.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2030). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NP7", "bibtex": "@misc{iqvia2030expectedkt7np7,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NP7},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNC", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNC", "indicator": { "slug": "expected-annual-novel-active-substance-launches-upper-bound", "name": "Expected annual novel active substance launches (upper bound)", "definition": "Upper bound of the projected average annual number of novel active substance launches over the next five years." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-01-01", "end": "2030-12-31", "type": "year" }, "value": 55, "value_text": "55", "unit": "count", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "Growth will be driven by the adoption of newly launched innovative products, with an average of 50–55 new medicines expected to launch annually over the next five years, including therapies in oncology, immunology, and other specialty areas, as well as more traditional treatments in diabetes, obesity, and neurology.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2030). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNC", "bibtex": "@misc{iqvia2030expectedkt7nnc,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNC},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NP8", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NP8", "indicator": { "slug": "expected-annual-novel-active-substance-launches-upper-bound", "name": "Expected annual novel active substance launches (upper bound)", "definition": "Upper bound of the projected average annual number of novel active substance launches over the next five years." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2030-12-31", "type": "year" }, "value": 80, "value_text": "80", "unit": "count", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025", "document_type": "press_release", "locator": "Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025", "quote": "Based on molecules in the late-stage pipeline and historic success rates, over the next five years an average of 70–80 NAS are expected to launch annually, expanding the number of NAS launched globally by 350–400.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2030). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NP8", "bibtex": "@misc{iqvia2030expectedkt7np8,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NP8},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NP9", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NP9", "indicator": { "slug": "expected-cumulative-novel-active-substance-launches-lower-bound", "name": "Expected cumulative novel active substance launches (lower bound)", "definition": "Lower bound of the projected total number of novel active substance launches over a five-year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2030-12-31", "type": "year" }, "value": 350, "value_text": "350", "unit": "count", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025", "document_type": "press_release", "locator": "Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025", "quote": "Based on molecules in the late-stage pipeline and historic success rates, over the next five years an average of 70–80 NAS are expected to launch annually, expanding the number of NAS launched globally by 350–400.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2030). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NP9", "bibtex": "@misc{iqvia2030expectedkt7np9,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NP9},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NPA", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPA", "indicator": { "slug": "expected-cumulative-novel-active-substance-launches-upper-bound", "name": "Expected cumulative novel active substance launches (upper bound)", "definition": "Upper bound of the projected total number of novel active substance launches over a five-year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2030-12-31", "type": "year" }, "value": 400, "value_text": "400", "unit": "count", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025", "document_type": "press_release", "locator": "Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025", "quote": "Based on molecules in the late-stage pipeline and historic success rates, over the next five years an average of 70–80 NAS are expected to launch annually, expanding the number of NAS launched globally by 350–400.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2030). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPA", "bibtex": "@misc{iqvia2030expectedkt7npa,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPA},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_P7WN878PVEMQ24Z7AEC6R92ZNM", "url": "https://statorigin.org/stat/stat_P7WN878PVEMQ24Z7AEC6R92ZNM", "indicator": { "slug": "fill-rate-for-novel-medicine-prescriptions-first-year", "name": "Fill rate for novel medicine prescriptions (first year)", "definition": "Average percentage of first-year new prescriptions for novel medicines that were filled." }, "industry": [ { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2020-01-01", "end": "2024-12-31", "type": "year" }, "value": 35, "value_text": "35%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "On average, 35% of these prescriptions were filled, while 65% went unfilled, including an average of 49% rejected by payers and 17% abandoned by patients after payer approval, likely due to high out‑of‑pocket costs.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T01:20:11.850Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2024). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_P7WN878PVEMQ24Z7AEC6R92ZNM", "bibtex": "@misc{iqvia2024fillr92znm,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_P7WN878PVEMQ24Z7AEC6R92ZNM},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T01:20:11.850Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NP0", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NP0", "indicator": { "slug": "first-in-class-novel-active-substance-launches", "name": "First-in-class novel active substance launches", "definition": "Number of launched novel active substances that represent a first-in-class mechanism." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 30, "value_text": "Thirty", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025", "document_type": "press_release", "locator": "Key Findings", "quote": "Thirty launches were global first-in-class", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NP0", "bibtex": "@misc{iqvia2025firstkt7np0,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NP0},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGCW", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCW", "indicator": { "slug": "first-in-class-novel-active-substance-launches", "name": "First-in-class novel active substance launches", "definition": "Number of launched novel active substances that represent a first-in-class mechanism." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 30, "value_text": "Thirty", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026", "document_type": "press_release", "locator": "The number of novel active substance (NAS) launches increased on a global basis", "quote": "Thirty launches were global first-in-class", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCW", "bibtex": "@misc{iqvia2025firstbjmgcw,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCW},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_JM2XHZ4K746FQVB9DGV1W2TYWT", "url": "https://statorigin.org/stat/stat_JM2XHZ4K746FQVB9DGV1W2TYWT", "indicator": { "slug": "first-year-new-prescriptions-for-novel-medicines-multi-year-total", "name": "First-year new prescriptions for novel medicines (multi-year total)", "definition": "Total volume of new prescriptions written during the first year of market availability for newly launched medicines." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2020-01-01", "end": "2024-12-31", "type": "year" }, "value": 7, "value_text": "7 million", "unit": "count", "currency": null, "scale": "million", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "For these medicines, 7 million new prescriptions were written in the first year of availability, with 64% related to RSV vaccines alone.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2024). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_JM2XHZ4K746FQVB9DGV1W2TYWT", "bibtex": "@misc{iqvia2024firstw2tywt,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_JM2XHZ4K746FQVB9DGV1W2TYWT},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_7Q206KR0B5YTYRQ523FNSCNP4R", "url": "https://statorigin.org/stat/stat_7Q206KR0B5YTYRQ523FNSCNP4R", "indicator": { "slug": "five-year-cumulative-medicine-use-growth", "name": "Five-year cumulative medicine use growth", "definition": "Cumulative percentage increase in prescription medicine use based on defined daily doses over a five-year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2020-01-01", "end": "2025-12-31", "type": "year" }, "value": 13, "value_text": "13%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "The use of prescription medicines in the U.S. — based on defined daily doses — has grown 13% in the last five years to 210 billion days of therapy across both retail and non‑retail settings, although growth slowed beginning in 2024.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_7Q206KR0B5YTYRQ523FNSCNP4R", "bibtex": "@misc{iqvia2025fivescnp4r,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_7Q206KR0B5YTYRQ523FNSCNP4R},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_R2MNGNMXCRYC3JE9Y6DC9EXHSH", "url": "https://statorigin.org/stat/stat_R2MNGNMXCRYC3JE9Y6DC9EXHSH", "indicator": { "slug": "five-year-cumulative-novel-active-substance-launches-excluding-covid-19", "name": "Five-year cumulative novel active substance launches excluding COVID-19", "definition": "Cumulative number of novel active substances launched over a five-year period, excluding COVID-19 vaccines and therapeutics." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2021-01-01", "end": "2025-12-31", "type": "year" }, "value": 369, "value_text": "369", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025", "document_type": "press_release", "locator": "Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025", "quote": "The 79 novel active substances launched globally in 2025 bring the five-year total to 388, or 369 excluding COVID-19 vaccines and therapeutics.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Via StatOrigin, https://statorigin.org/stat/stat_R2MNGNMXCRYC3JE9Y6DC9EXHSH", "bibtex": "@misc{iqvia2025five9exhsh,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_R2MNGNMXCRYC3JE9Y6DC9EXHSH},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NN0", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN0", "indicator": { "slug": "forecast-list-price-medicine-spending-growth-lower-bound", "name": "Forecast list-price medicine spending growth lower bound", "definition": "Projected lower-bound compound annual growth rate of medicine spending at list prices." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-01-01", "end": "2030-12-31", "type": "year" }, "value": 6, "value_text": "6", "unit": "percent", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Key Findings", "quote": "U.S. medicine spending at net prices is forecast to grow 4.5 to 7.5% through 2030, while 6 to 9% at list prices", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2030). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN0", "bibtex": "@misc{iqvia2030forecastkt7nn0,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN0},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NN1", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN1", "indicator": { "slug": "forecast-list-price-medicine-spending-growth-upper-bound", "name": "Forecast list-price medicine spending growth upper bound", "definition": "Projected upper-bound compound annual growth rate of medicine spending at list prices." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-01-01", "end": "2030-12-31", "type": "year" }, "value": 9, "value_text": "9%", "unit": "percent", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Key Findings", "quote": "U.S. medicine spending at net prices is forecast to grow 4.5 to 7.5% through 2030, while 6 to 9% at list prices", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2030). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN1", "bibtex": "@misc{iqvia2030forecastkt7nn1,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN1},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NMY", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMY", "indicator": { "slug": "forecast-net-medicine-spending-growth-lower-bound", "name": "Forecast net medicine spending growth lower bound", "definition": "Projected lower-bound compound annual growth rate of medicine spending at net prices." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-01-01", "end": "2030-12-31", "type": "year" }, "value": 4.5, "value_text": "4.5", "unit": "percent", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Key Findings", "quote": "U.S. medicine spending at net prices is forecast to grow 4.5 to 7.5% through 2030, while 6 to 9% at list prices", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2030). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMY", "bibtex": "@misc{iqvia2030forecastkt7nmy,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMY},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NMZ", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMZ", "indicator": { "slug": "forecast-net-medicine-spending-growth-upper-bound", "name": "Forecast net medicine spending growth upper bound", "definition": "Projected upper-bound compound annual growth rate of medicine spending at net prices." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-01-01", "end": "2030-12-31", "type": "year" }, "value": 7.5, "value_text": "7.5%", "unit": "percent", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Key Findings", "quote": "U.S. medicine spending at net prices is forecast to grow 4.5 to 7.5% through 2030, while 6 to 9% at list prices", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2030). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMZ", "bibtex": "@misc{iqvia2030forecastkt7nmz,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMZ},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NN9", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN9", "indicator": { "slug": "gip-glp-1-agonist-spending-growth-contribution", "name": "GIP/GLP-1 agonist spending growth contribution", "definition": "Annual monetary growth contributed by GIP/GLP-1 agonist medicines across diabetes and obesity indications." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 14, "value_text": "$14 billion", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "GIP/GLP‑1 agonists across diabetes and obesity contributed $14 billion in growth, with $9.6 billion concentrated in products approved for obesity and related comorbidities.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN9", "bibtex": "@misc{iqvia2025agonistkt7nn9,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN9},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_Y00FWJA0G98BZFXKZGJHKACAY0", "url": "https://statorigin.org/stat/stat_Y00FWJA0G98BZFXKZGJHKACAY0", "indicator": { "slug": "growth-in-cancer-medicine-spending", "name": "Growth in cancer medicine spending", "definition": "Cumulative percentage increase in total spending on cancer medicines over a specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2019-01-01", "end": "2024-12-31", "type": "year" }, "value": 75, "value_text": "75%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global Oncology Trends 2025", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025", "document_type": "press_release", "locator": "Other Findings", "quote": "Spending on cancer medicines, not including additional medical costs or supportive care medicines, grew 75% over the last five years, reaching $252Bn in 2024.", "published_date": null, "accessed_at": "2026-09-16", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2024). Global Oncology Trends 2025. Retrieved September 16, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Via StatOrigin, https://statorigin.org/stat/stat_Y00FWJA0G98BZFXKZGJHKACAY0", "bibtex": "@misc{iqvia2024growthkacay0,\n author = {{IQVIA Institute}},\n title = {Global Oncology Trends 2025},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_Y00FWJA0G98BZFXKZGJHKACAY0},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Accessed September 16, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NMR", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMR", "indicator": { "slug": "high-gdp-developed-countries-medicine-spending-growth", "name": "High GDP developed countries medicine spending growth", "definition": "Projected medicine spending growth for a group of 14 larger high GDP countries excluding the United States." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2025-01-01", "end": "2030-12-31", "type": "year" }, "value": 155.1, "value_text": "$155.1Bn", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-medicine-use-trends-2026", "document_type": "press_release", "locator": "Exhibit 20: High growth developed and Pharmerging markets spending and growth,constant US$, 2015–2030", "quote": "There are 14 larger growth high GDP countries (excluding the U.S.) which are projected to grow by $155.1Bn through 2030, with 83% of the growth from the top eight of these countries.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2030). Global Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMR", "bibtex": "@misc{iqvia2030highkt7nmr,\n author = {{IQVIA Institute}},\n title = {Global Medicine Use Trends 2026},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMR},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_7SP4SR6JPRTVB64YXZ1GZWFJE1", "url": "https://statorigin.org/stat/stat_7SP4SR6JPRTVB64YXZ1GZWFJE1", "indicator": { "slug": "inter-trial-interval-increase", "name": "Inter-trial interval increase", "definition": "Increase in the average duration between clinical trial phases or program milestones." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 3, "value_text": "3 months", "unit": "months", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026", "document_type": "press_release", "locator": "Key Findings:", "quote": "Inter-trial intervals increased by 3 months", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_7SP4SR6JPRTVB64YXZ1GZWFJE1", "bibtex": "@misc{iqvia2025interzwfje1,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_7SP4SR6JPRTVB64YXZ1GZWFJE1},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_W560S45SS5JAN21YBEKN25HTMW", "url": "https://statorigin.org/stat/stat_W560S45SS5JAN21YBEKN25HTMW", "indicator": { "slug": "large-company-small-molecule-share-of-phase-i-clinical-trial-starts", "name": "Large company small molecule share of Phase I clinical trial starts", "definition": "Percentage of Phase I clinical trial starts sponsored by large pharmaceutical companies that investigate small molecule drugs." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2022-01-01", "end": "2022-12-31", "type": "year" }, "value": 61, "value_text": "61%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025", "document_type": "press_release", "locator": "Exhibit 21: Small molecule share of trial starts by phase and company segment, 2016–2025", "quote": "The recent increase in the proportion of small molecule trials in Phase I has been driven by a combination of stabilization of small molecule share among EBPs and an increasing share of small molecule trials among larger companies, where the small molecule share increased from 61% in 2022 to 66% in 2025.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2022). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Via StatOrigin, https://statorigin.org/stat/stat_W560S45SS5JAN21YBEKN25HTMW", "bibtex": "@misc{iqvia2022large25htmw,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2022},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_W560S45SS5JAN21YBEKN25HTMW},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_HMR9RWQCV8ZAV85EK7C6V3R03Z", "url": "https://statorigin.org/stat/stat_HMR9RWQCV8ZAV85EK7C6V3R03Z", "indicator": { "slug": "large-company-small-molecule-share-of-phase-i-clinical-trial-starts", "name": "Large company small molecule share of Phase I clinical trial starts", "definition": "Percentage of Phase I clinical trial starts sponsored by large pharmaceutical companies that investigate small molecule drugs." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 66, "value_text": "66%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025", "document_type": "press_release", "locator": "Exhibit 21: Small molecule share of trial starts by phase and company segment, 2016–2025", "quote": "The recent increase in the proportion of small molecule trials in Phase I has been driven by a combination of stabilization of small molecule share among EBPs and an increasing share of small molecule trials among larger companies, where the small molecule share increased from 61% in 2022 to 66% in 2025.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Via StatOrigin, https://statorigin.org/stat/stat_HMR9RWQCV8ZAV85EK7C6V3R03Z", "bibtex": "@misc{iqvia2025largev3r03z,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_HMR9RWQCV8ZAV85EK7C6V3R03Z},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_99TTKTY67GT4JSSS1WATAF78VE", "url": "https://statorigin.org/stat/stat_99TTKTY67GT4JSSS1WATAF78VE", "indicator": { "slug": "large-company-small-molecule-share-of-phase-i-clinical-trial-starts", "name": "Large company small molecule share of Phase I clinical trial starts", "definition": "Percentage of Phase I clinical trial starts sponsored by large pharmaceutical companies that investigate small molecule drugs." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2022-01-01", "end": "2022-12-31", "type": "year" }, "value": 61, "value_text": "61%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026", "document_type": "press_release", "locator": "Exhibit 21: Small molecule share of trial starts by phase and company segment, 2016–2025", "quote": "The recent increase in the proportion of small molecule trials in Phase I has been driven by a combination of stabilization of small molecule share among EBPs and an increasing share of small molecule trials among larger companies, where the small molecule share increased from 61% in 2022 to 66% in 2025.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2022). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_99TTKTY67GT4JSSS1WATAF78VE", "bibtex": "@misc{iqvia2022largeaf78ve,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2022},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_99TTKTY67GT4JSSS1WATAF78VE},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_701X1CHRKM0KE3H38P47WW3C0N", "url": "https://statorigin.org/stat/stat_701X1CHRKM0KE3H38P47WW3C0N", "indicator": { "slug": "large-company-small-molecule-share-of-phase-i-clinical-trial-starts", "name": "Large company small molecule share of Phase I clinical trial starts", "definition": "Percentage of Phase I clinical trial starts sponsored by large pharmaceutical companies that investigate small molecule drugs." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 66, "value_text": "66%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026", "document_type": "press_release", "locator": "Exhibit 21: Small molecule share of trial starts by phase and company segment, 2016–2025", "quote": "The recent increase in the proportion of small molecule trials in Phase I has been driven by a combination of stabilization of small molecule share among EBPs and an increasing share of small molecule trials among larger companies, where the small molecule share increased from 61% in 2022 to 66% in 2025.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_701X1CHRKM0KE3H38P47WW3C0N", "bibtex": "@misc{iqvia2025largeww3c0n,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_701X1CHRKM0KE3H38P47WW3C0N},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_8J3C6WP1FE8YZ13MEAG6AZNK1D", "url": "https://statorigin.org/stat/stat_8J3C6WP1FE8YZ13MEAG6AZNK1D", "indicator": { "slug": "life-sciences-and-patient-organization-deal-value", "name": "Life sciences and patient organization deal value", "definition": "Estimated total aggregate value of publicly announced deals between patient organizations and life sciences companies." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2008-01-01", "end": "2023-10-05", "type": "point" }, "value": 2.4, "value_text": "$2.4 billion", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "estimate", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Supporting patients through research collaboration", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration", "document_type": "press_release", "locator": "Key findings:", "quote": "Nearly 700 deals with an estimated aggregate value of $2.4 billion have been publicly announced between patient organizations and life sciences companies over the past 15 years.", "published_date": null, "accessed_at": "2026-09-16", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Supporting patients through research collaboration. Retrieved September 16, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration. Via StatOrigin, https://statorigin.org/stat/stat_8J3C6WP1FE8YZ13MEAG6AZNK1D", "bibtex": "@misc{iqvia2023lifeaznk1d,\n author = {{IQVIA Institute}},\n title = {Supporting patients through research collaboration},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_8J3C6WP1FE8YZ13MEAG6AZNK1D},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration. Accessed September 16, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_VMCR6QGZ4YDG5FFXQ3H2SKPE7C", "url": "https://statorigin.org/stat/stat_VMCR6QGZ4YDG5FFXQ3H2SKPE7C", "indicator": { "slug": "life-sciences-and-patient-organization-deals", "name": "Life sciences and patient organization deals", "definition": "Number of publicly announced deals between patient organizations and life sciences companies." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2008-01-01", "end": "2023-10-05", "type": "point" }, "value": 700, "value_text": "700", "unit": "count", "currency": null, "scale": "1", "value_type": "estimate", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Supporting patients through research collaboration", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration", "document_type": "press_release", "locator": "Key findings:", "quote": "Nearly 700 deals with an estimated aggregate value of $2.4 billion have been publicly announced between patient organizations and life sciences companies over the past 15 years.", "published_date": null, "accessed_at": "2026-09-16", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Supporting patients through research collaboration. Retrieved September 16, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration. Via StatOrigin, https://statorigin.org/stat/stat_VMCR6QGZ4YDG5FFXQ3H2SKPE7C", "bibtex": "@misc{iqvia2023lifeskpe7c,\n author = {{IQVIA Institute}},\n title = {Supporting patients through research collaboration},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_VMCR6QGZ4YDG5FFXQ3H2SKPE7C},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration. Accessed September 16, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" } ] }, "meta": { "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.", "license": "https://creativecommons.org/licenses/by/4.0/", "docs": "https://statorigin.org/docs/api", "total": 100, "note": "Statistics are capped at 100 per request. Use /statistics?source_org=iqvia-institute with a cursor to page through everything." } }